A Mobile Application Guiding Patients With Type 1 Diabetes Using Sensor-Augmented Insulin Pump Therapy

Esvant, A.; Lefebvre, Marie-Anne; Campillo‐Gimenez, Boris; Lannes, Morgane; Delamarre, Denis; Guilhem, Isabelle; Poirier, Jean-Yves

doi:10.1177/1932296816633486

Cited by 6 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several recent studies have shown that use of rtCGM in conjunction with CSII treatment reduces HbA1c levels and occurrence severe of hypoglycemia and/or duration of hypoglycemia in pediatric and adult T1D populations. 7,14,[18][19][20][21] However, recent evidence suggests that rtCGM use in conjunction with MDI treatment may provide the similar glycemic benefits without the additional costs associated with CSII therapy. 22 Our study found that use of rtCGM was associated with reduced HbA1c and utilization of health services compared with SMBG use regardless of insulin delivery method.…”

Section: Discussionmentioning

confidence: 99%

“…7,14,[18][19][20][21] However, recent evidence suggests that rtCGM use in conjunction with MDI treatment may provide the similar glycemic benefits without the additional costs associated with CSII therapy. 22 Our study found that use of rtCGM was associated with reduced HbA1c and utilization of health services compared with SMBG use regardless of insulin delivery method.…”

Section: Discussionmentioning

confidence: 99%

“…3,6-15 Importantly, the benefits of rtCGM are seen primarily in individuals who wear their devices frequently and act appropriately on the glucose data provided. 3,6,16-18 Most of the evidence supporting rtCGM use comes from studies conducted primarily in patients using continuous subcutaneous insulin infusion (CSII); 7,14,18-21 however, results from a recent study of 20 adult T1D patients suggest that rtCGM may confer the same glycemic benefits to patients treated with multiple daily insulin injection (MDI) therapy. 22…”

mentioning

confidence: 99%

“…(CSII); 7,14,[18][19][20][21] however, results from a recent study of 20 adult T1D patients suggest that rtCGM may confer the same glycemic benefits to patients treated with multiple daily insulin injection (MDI) therapy. 22 The large financial burden of diabetes is growing and unsustainable, and clinicians are challenged to select treatment regimens that are both efficacious and cost-effective.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Continuous Glucose Monitoring Use in Type 1 Diabetes: Longitudinal Analysis Demonstrates Meaningful Improvements in HbA1c and Reductions in Health Care Utilization

Parkin¹,

Graham

Smolskis

2017

J Diabetes Sci Technol

View full text Add to dashboard Cite

Background: Real-time continuous glucose monitoring (rtCGM) improves glycemic control in type 1 diabetes (T1D) patients treated with continuous subcutaneous insulin infusion (CSII). However, the benefits of rtCGM in T1D patients treated with multiple daily insulin injection (MDI) therapy has not been well studied. We explored the effects of rtCGM versus self-monitoring of blood glucose (SMBG) on clinical outcomes within a large T1D population treated with either CSII or MDI therapy. Methods: This retrospective, longitudinal analysis utilized datasets from T1D patients enrolled in a commercial health plan to assess changes in HbA1c in 187 naïve to rtCGM users and 6260 SMBG users. Propensity score modeling was used to assess inpatient admissions, emergency room (ER) visits in 1130 patients (565 rtCGM, 565 SMBG). Differences in HbA1c reduction (rtCGM+MDI vs rtCGM+CSII) were evaluated. Results: Larger, clinically meaningful HbA1c reductions were seen among rtCGM versus SMBG users: –0.5% (P = .004) versus −0.2% (P < .0001); 0.3% diff in diff, P = .03. All-cause inpatient admissions were lower for rtCGM users: –42%, P = .013. Emergency room visits coded for diabetic ketoacidosis (DKA) were four times higher for SMBG patients than rtCGM patients: 17 versus 4, P = .0318. HbA1c reductions were most notable with rtCGM+MDI versus rtCGM+CSII treatment: –0.6% (P = .01) versus −0.3% (P = .16). Conclusions: Use of rtCGM in T1D patients facilitates greater HbA1c improvements and reduced health care system utilization compared with traditional SMBG use regardless of insulin administration method. Treatment with rtCGM in conjunction with MDI confers similar or greater glycemic benefits without the additional costs associated with CSII therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Continuous Glucose Monitoring Use in Type 1 Diabetes: Longitudinal Analysis Demonstrates Meaningful Improvements in HbA1c and Reductions in Health Care Utilization

Parkin¹,

Graham

Smolskis

2017

J Diabetes Sci Technol

View full text Add to dashboard Cite

show abstract

“…According to Brzan et al, 21 sensor-based applications accurately estimate the insulin dosage to avoid human errors. In the study by Esvant et al, 22 a Bluetooth sensor-based smartphone application is developed to make the process of disease management of Type 1 and Type 2 patients feasible. A Contour Plus ONE sensor is recommended to be used along with this smartphone application.…”

Section: Related Workmentioning

confidence: 99%

Smart applications for diabetes management: A comprehensive survey and ranking

Rehman¹,

Aleem

Islam

et al. 2019

Health Informatics J

View full text Add to dashboard Cite

Diabetes is a chronic disease, and its treatment requires intensive management of medication, diet, and exercise. Nowadays, information and communication technology provides diverse facilities to patients and medical specialists to manage different diseases in an efficient manner with the help of smartphone technology. Earlier studies have not ranked diabetes management apps by correlating each app feature, and their review is not comprehensive. Therefore, this study presents a comprehensive analysis of the existing diabetes-related smartphone applications. Moreover, we examine the factors based on which most of the users provide a higher rank to a particular application. We classify the diabetes mobile applications with respect to the application features and perform rigorous analysis of the top 15 applications. The results indicate that there exists a weak correlation between the number of downloads and user ratings. For evaluation, we calculate the normalized discounted cumulative gain score to rank applications based on its features. The results demonstrate that a higher normalized discounted cumulative gain score is attained by those mobile applications that contain the data-sharing feature.

show abstract